



Molecular Crystals and Liquid Crystals Science and Technology. Section A. Molecular Crystals and Liquid Crystals

Publication details, including instructions for authors and subscription information:
<http://www.tandfonline.com/loi/gmcl19>

Crystal and Molecular Structure of Synthetic Antidiabetic Compound: Derivatives of Tetrahydro Indoles-(1-N-Butyl-2,6,6'-Trimethyl-4-Oxo-4,5,6,7-Tetrahydro-3 Indole Acetic Acid) and Modeling Studies

K. Rajalakshmi^a, S. Deepthi^a, Vasantha Pattabhi^{a,c} & K. Nagarajan^b

^a Department of Crystallography and BioPhysics, University of Madras, Guindy Campus, Madras, 600025, India

^b Recon Limited, R&D Centre, 32/1, Kalena Agrahara, Bannarghatta Road, Bangalore, 560076, India

^c Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai, 600 025, India Phone: 91-044-2353167 Fax: 91-044-2353167 E-mail:

Version of record first published: 24 Sep 2006

To cite this article: K. Rajalakshmi, S. Deepthi, Vasantha Pattabhi & K. Nagarajan (2001): Crystal and Molecular Structure of Synthetic Antidiabetic Compound: Derivatives of Tetrahydro Indoles-(1-N-Butyl-2,6,6'-Trimethyl-4-Oxo-4,5,6,7-Tetrahydro-3 Indole Acetic Acid) and Modeling Studies, *Molecular Crystals and Liquid Crystals Science and Technology. Section A. Molecular Crystals and Liquid Crystals*, 357:1, 281-289

To link to this article: <http://dx.doi.org/10.1080/10587250108028260>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Crystal and Molecular Structure of Synthetic Antidiabetic Compound: Derivatives of Tetrahydro Indoles- (1-N-Butyl-2,6,6'-Trimethyl-4-Oxo-4,5,6,7-Tetrahydro-3 Indole Acetic Acid) and Modeling Studies

K. RAJALAKSHMI^a, S. DEEPTHI^a, VASANTHA PATTABHI^{a*} and K. NAGARAJAN^b

^a*Department of Crystallography and BioPhysics, University of Madras, Guindy Campus, Madras-600025, India and* ^b*Recon Limited, R&D Centre, 32/1, Kalena Agrahara, Bannarghatta Road, Bangalore-560076, India*

(Received May 06, 2000; In final form July 27, 2000)

The crystal and molecular structure of (1-n-butyl-2,6,6'-trimethyl-4-oxo - 4,5,6,7 - tetrahydro - 3 indole acetic acid) with desirable anti hyperglycemic properties is reported. The title compound crystallises in orthorhombic space group Pbc_a with $z = 8$. The unit cell dimensions are $a = 15.698(13)\text{\AA}$, $b = 11.639(2)\text{\AA}$, $c = 18.506(3)\text{\AA}$, $V = 3381.2(29)\text{\AA}^3$, $D_{\text{calc}} = 1.145\text{Mg/m}^3$. The cyclohexane ring adopts a sofa conformation. The structure is stabilized by C-H...O and O-H...O hydrogen bonds. Molecular modeling studies on this class of compounds and the classical antidiabetic agent tolbutamide reveal a structural basis for the similar biological activity exhibited by two totally structurally unrelated compounds.

Keywords: Anti diabetic compounds; modeling studies; Crystalstructure; Hypoglycemic agents; Tetrahydro indole derivatives

* Address for correspondence: Dr. VASANTHA PATTABI, Professor, Department of Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai -600 025, India. E-mail: Crystal@giasmd01.vsnl.net.in Tel: -91-044-2353167 extn.211, Fax: -91-044-2352494.

INTRODUCTION

Among major endocrinal disorders in humans, non-insulin-dependent diabetes melitus(NIDDM) is assuming alarming global proportions, affecting 50–60 million people worldwide[1,2]. Of various factors related to the etiology of NIDDM, insulin deficiency has been identified to be the major cause which may be the result of insufficient secretion of insulin or desensitization of insulin receptors. Until recently, insulin secretagogues [2] like tolbutamide **1** and glibenclamide and to a lesser extent, biguanides (eg. metformin) have been used for the treatment of NIDDM. The former act by stimulating the release of insulin from the pancreas and the second presumably by extrapancreatic mechanisms[1]. In the last couple of years, insulin sensitizers belonging to the glitazone group have assumed importance among which troglitazone[3] and very recently rosiglitazone[4] have been introduced to clinical practice, but infrequent reports of liver disfunction have bedeviled some of the glitazones[2]. We had published earlier on a 4-oxo tetrahydroindole derivative, CGI 14600 as an insulin secretagogue with potency and profile similar to glibenclamide[5] and carried out modeling studies[6]. We had also synthesized [7] a class of 4-oxo-4,5,6,7-tetrahydroindole-3-acetic acids with hyperglycemic activity among which the 1-*n*-butyl **2**(GO8778) and 1-iso-butyl **3**(GO9001) were the most potent with activity comparable to tolbutamide **1** in the normal fasted rat. Interestingly, unlike **1**, **2** and **3** were also active in the streptozotocin-diabetic rat like metformin. Their profile included desirable features like no effect on blood lactate levels and decreasing liver glycogen level in the non- fasted rat and no inhibition of gluconeogenesis in rat[8]. Additionally they were relatively nontoxic in acute studies. In view of potential usefulness of new structural leads of this type in the treatment of diabetes, we have carried out crystallographic molecular modeling studies on **2** and **3** in relation to tolbutamide **1**. These could possibly help design newer antidiabetic molecules with useful profile and improved safety. The results are presented in this paper.

EXPERIMENTAL

2(GO8778) was synthesised from dimedone in three steps – addition to maleic acid, treatment of the adduct with acetic anhydride and reaction of the resultant triketoacid with *n*-butyl amine in acetic acid. Use of isobutyl amine in the last step in place of *n*-butyl gave **3**(GO9001).

Crystals of **2** and **3** were obtained from toluene and benzene respectively. We have carried out single crystal X-ray studies on both the compounds. Details of the structure analysis of **3** have been published[9]. The results obtained for the crystal structure of **2** is reported here.

TABLE I Atomic coordinates ($\times 10^4$) and equivalent isotropic displacement parameters ($\text{\AA}^2 \times 10^3$) of non-hydrogen atoms with e.s. d's in paranthesis for **2**

Atom	x	y	z	U(eq)
N(1)	2102(2)	851(3)	3460(2)	87(1)
C(1)	-544(1)	1850(6)	4794(3)	151(2)
C(2)	-139(3)	1094(6)	4227(3)	123(2)
C(3)	789(3)	1317(5)	4167(3)	109(2)
C(4)	1229(3)	494(4)	3619(3)	98(2)
C(5)	2310(3)	1673(4)	2970(3)	82(1)
C(6)	3176(3)	1837(4)	3013(2)	76(1)
C(7)	3507(3)	1095(4)	3558(2)	80(1)
C(8)	2831(3)	496(4)	3824(3)	88(1)
C(9)	2808(3)	-402(5)	4401(3)	126(2)
C(10)	4413(3)	1001(4)	3817(3)	93(2)
C(11)	4900(4)	-2(6)	3521(5)	108(2)
C(12)	1711(3)	2310(4)	2503(2)	99(2)
C(13)	2166(3)	2829(4)	1856(2)	85(1)
C(14)	2376(4)	1886(5)	1312(3)	135(2)
C(15)	1588(3)	3695(5)	1484(3)	127(2)
C(16)	2975(3)	3411(4)	2103(3)	108(2)
C(17)	3583(4)	2683(4)	2569(3)	95(2)
O(1)	4358(2)	2885(3)	2577(2)	118(1)
O(2)	4842(9)	-243(13)	2924(6)	122(5)
O(3)	5382(12)	-550(15)	3950(5)	196(9)
O(2')	4730(15)	-690(20)	3090(20)	229(18)
O(3')	5589(14)	140(30)	3660(30)	330(20)

where $U_{eq} = 1/3 \sum_i \sum_j a_i a_j a_i^* a_j^*$

Crystal structure of **2**

A colourless needle shaped crystal of dimension $0.45 \times 0.075 \times 0.125$ mm was selected for X-ray data collection. All X-ray measurements were made at room temperature on an ENRAF-NONIUS (CAD-4 diffractometer)[13] using $\text{CuK}\alpha$ radiation ($\lambda=1.5418\text{\AA}$). The cell refinement and data reduction was done using CAD4-software[10]. The data were collected at 293K using ($\omega/2\theta$) scanning mode. Least-squares refinement of 25 well-centered reflection in the ranges $8^\circ \leq \theta \leq 22^\circ$ yielded a primitive orthorhombic cell. During data collection three standard reflections periodically monitored showed no significant intensity variation. Corrections for Lorentz and polarisation factors were applied to intensity value but no absorption correction was made. A total of 2996 intensities were collected in the range $4.78^\circ \leq \theta \leq 69.87^\circ$ of which 2994 were unique ($R_{int}=0.039$).

The structure was solved by means of direct methods SHELXS97 [11] and refined by full matrix least-squares method on $|F|^2$ using SHELXL97 [12]. Final refinement was carried out with anisotropic thermal parameters for all non H atoms. All the Hydrogens were geometrically fixed and allowed to ride on corresponding carbon atoms. The final cycle of full matrix refinement based on 2994 observed reflection ($I > 4\sigma(I)$) and 214 parameters converged to $R = 0.069$ with goodness of fit = 0.956. The largest peak and the deepest hole in the final difference map were 0.217 and $-0.191 \text{ e. \AA}^{-3}$ respectively. The final positional co-ordinates of all atoms with equivalent isotropic thermal parameters, bond distances and bond angles for non-hydrogen atoms are listed in Tables I- II. Fig. 1 was plotted (displacement ellipsoids are drawn at 30% probability level) using ZORTEP Programme [16].

TABLE II Bond lengths (\AA) and Bond angles ($^\circ$) of non- hydrogen atoms with e.s. d's in paranthesis for **2**

<i>Atoms</i>	<i>Length</i>	<i>Atoms</i>	<i>Length</i>
N(1)-C(5)	1.358(5)	N(1)-C(8)	1.390(5)
N(1)-C(4)	1.463(5)	C(1)-C(2)	1.510(7)
C(2)-C(3)	1.483(6)	C(3)-C(4)	1.556(6)
C(5)-C(6)	1.375(6)	C(5)-C(12)	1.476(6)
C(6)-C(7)	1.426(6)	C(6)-C(17)	1.432(6)
C(7)-C(8)	1.361(6)	C(7)-C(10)	1.505(6)
C(8)-C(9)	1.495(6)	C(10)-C(11)	1.499(8)
C(11)-O(2)	1.143(12)	C(11)-O(3)	1.270(13)
C(12)-C(13)	1.520(5)	C(13)-C(16)	1.511(6)
C(13)-C(15)	1.520(6)	C(13)-C(14)	1.526(6)
C(16)-C(17)	1.541(6)	C(17)-O(1)	1.239(5)
C(5)-N(1)-C(8)	109.5(4)	C(5)-N(1)-C(4)	124.1(4)
C(8)-N(1)-C(4)	126.1(4)	C(3)-C(2)-C(1)	111.4(5)
C(2)-C(3)-C(4)	112.1(5)	N(1)-C(4)-C(3)	111.8(4)
N(1)-C(5)-C(6)	107.3(4)	N(1)-C(5)-C(12)	126.3(4)
C(6)-C(5)-C(12)	126.4(5)	C(5)-C(6)-C(7)	108.4(4)
C(5)-C(6)-C(17)	120.3(5)	C(7)-C(6)-C(17)	131.3(4)
C(8)-C(7)-C(6)	106.5(4)	C(8)-C(7)-C(10)	125.7(5)
C(6)-C(7)-C(10)	127.8(4)	C(7)-C(8)-N(1)	108.3(4)
C(7)-C(8)-C(9)	129.5(5)	N(1)-C(8)-C(9)	122.2(5)
C(11)-C(10)-C(7)	115.0(5)	O(2)-C(11)-O(3)	122.0(9)
O(3)-C(11)-C(10)	117.8(9)	C(5)-C(12)-C(13)	111.3(4)
C(16)-C(13)-C(12)	109.6(4)	C(16)-C(13)-C(15)	110.0(4)
C(12)-C(13)-C(15)	109.9(4)	C(16)-C(13)-C(14)	109.9(4)
C(12)-C(13)-C(14)	109.6(4)	C(15)-C(13)-C(14)	107.9(4)
C(13)-C(16)-C(17)	116.4(4)	O(1)-C(17)-C(6)	124.2(4)
O(1)-C(17)-C(16)	120.7(5)	C(6)-C(17)-C(16)	115.0(4)
O(2)-C(11)-C(10)	120.2(9)		

RESULTS AND DISCUSSIONS

The packing of the molecule is established by intermolecular O-H...O and C-H...O hydrogen bonds (Table III). The average e.s.d in bond lengths and bond angles are 0.006 Å and 0.5°. The five-membered ring and carboxyl group are planar within experimental error. The cyclohexane ring is in the sofa conformation. The best plane passing through the five membered ring makes a dihedral angle of 4.3(2)° with the best plane passing through the cyclohexane ring. The carboxyl group oxygens are disordered with occupancies 0.6 and 0.4. This compound is known to loose carbon dioxide at room temperature if stored for a long period of time. The disorder of this group may be due to this phenomenon. Perspective view of **1**, **2** and **3** are shown in Figure 2 with the atom numbering schemes.




FIGURE 1 ZORTEP diagram of compound **2** with 50% probability displacement ellipsoids

TABLE III Hydrogen Bonds of **2**


<i>Donor(D)</i>	<i>Acceptor(A)</i>	<i>D...A(Å)</i>	<i>H...A(Å)</i>	<i>D-H...A(°)</i>	<i>Symmetry</i>
O(2) ^a -H(2)	H(2)...O(1)	2.7(1)	1.9(4)	152(4)	(4)
C(12)-H(12A)	H(12A)...O(2')	3.4(4)	2.5(4)	155(1)	(2)
C(14)-H(14B)	H(14B)...O(3')	3.5(5)	2.5(5)	165(1)	(3)
C(16)-H(16B)	H(16B)...O(3) ^a	3.5(4)	2.6(4)	152(1)	(1)
Equivalent positions	(1) -x+1, y+1/2, -z+1/2 (2) -x+1/2, y+1/2, z (3) x-1/2, y, -z+1/2 (4) -x+1, y-1/2, z+1/2				

a. O2 and O3 are disordered, O2' and O3' are the alternate positions of O2 and O3. Hydrogens for O2 was fixed and not refined

Structure Activity correlation


As noted in our previous study of CGI 14600[6] the conformation observed in the crystal structure could be the only one or one of the possible bio-active conformation. Additionally we have carried out energy calculations for single bond rotations in **2** and **3**, using BIOSYM software [14] and CFF 91 forcefield. Thus in **2**, C8-N1-C4-C3 torsion angle (91.1°) was monitored. The energy value for the crystal structure, -5.15 Kcal/mole was nearly the same when this torsion was rotated through 180° (-5.17 Kcal/mole).

Likewise in **3** with C8-N1-C4-C3 angle (77.2°), the energy value of the crystal structure (4.4 Kcal/mole) was nearly the same. In both cases, the crystal conformations correspond very nearly to the minimum energy conformations of the isolated molecules. Thus although crystal structures are not always dependable indicators for determination of bio-active conformations, there is justification to believe that they may still represent rough approximations of the same. Hence these molecules were superimposed in their crystalline state conformations with tolbutamide **1**[15] in order to determine the degree of overlap of marker groups. The best fit was obtained with superposition of N2-C5-O3-N1-C4 group in **1** with C7-C8-C9-N1-C4 framework of **2** and **3** with r.m.s deviation of 1.106Å and 1.107Å respectively. Table IV shows the relevant torsion angles of **1,2,3** in the superposed region. It can be seen that the hydrophobic and hydrophilic regions of **2** and **3** superpose very well with those of **1** (Figure 3) explaining their common biological activity. Thus the regions indicated in Figure 3. may be important for the receptor binding. The result agrees with our earlier comparison of another 4-oxo-1,2,3,4-tetrahydroindole with glibenclamide[6]. It appears in these cases

FIGURE 2 Perspective view of **1**, **2** and **3** with atom numbering schemes

that N-1, C-8 and C-7 of the indole moiety and NHCONH unit in **1** may serve as spacers. Additionally the cyclohexane ring of **2** and **3** may play an auxiliary role in binding to hydrophobic pocket in the receptor.

The study offers a plausible hypothesis for the common biological activity and relationships of the 2-substituted-4,5,6,7,-tetrahydroindole acetic acids **2** and **3**

FIGURE 3 Superposition **1**, **2** and **3** showing the probable receptor binding site

on the one hand and tolbutamide **1** on the other and offers some clues to the receptor topography. This approach may help design newer molecules with better activity profile and clinical utility.

TABLE IV Torsion angles of **1**, **2** and **3** ($^{\circ}$) involving non- hydrogen atoms with e.s. d's in paranthesis

<i>Bonds</i>	<i>1</i>	<i>2</i>	<i>3</i>
C(1)-C(2)-C(3)-C(4)	-70.0(4)	176.4(2)	—
C(2)-C(3)-C(4)-N(1)	-178.2(3)	169.3(2)	-175.1(2)
C(3)-C(4)-N(1)-C(5)	88.3(3)	-82.5(2)	77.2(2)
C(4)-N(1)-C(8)-C(7)	-178.0(2)	-174.8(2)	179.2(2)
[C(4)-N(1)-C(5)-N(2)] ^a			
N(1)-C(8)-C(7)-C(10)	157.0(2)	178.0(2)	177.7(2)
[N(1)-C(5)-N(2)-S(1)] ^a			
C(8)-C(7)-C(10)-C(11)	59.0(2)	81.1(2)	104.2(2)
[C(5)-N(2)-S(1)-O(1)] ^a			
C(7)-C(10)-C(11)-O(3)	-171.0(2)	-138.7(2)	-108.8(3)
[C(5)-N(2)-S(1)-O(1)] ^a			
C(7)-C(10)-C(11)-O(2)	—	42.2(2)	71.2(3)

a. Tolbutamide numbering as given in Tolbutamide structure¹⁵

Acknowledgements

KR thanks UGC under FIP Program for the financial assistance.

References

- [1] S.N. Davis and D.K. Granner, Goodman & Gilman's The Pharmacological basis of Therapeutics, Mc-Graw Hill, NewYork, 1493(1996).
- [2] J. Cobb and I. Dukes, Ann. Report. Med. Chem., 33, 213(1998).
- [3] H. Hulin, P.A. McCarthy, and F.M. Gibbs, Curr. Pharmacol. Des., 2,85 (1996).
- [4] B.C.C. Cantello, M.A. Cawthorne, D. Haigh, R.M. Hindely, S.A. Smith and P.L. Thurbly, Bioorg. Med. Chem. Lett., 4, 1189(1994).
- [5] K. Nagarajan, P.K. Talwalker, and S.J. Shenoy, Europ. J. Med. Chem., 23, 189(1988).
- [6] V. Pattabhi, S. Vasundara, K Nagarajan, and S.J Shenoy, Med. Chem.Res., 4,196(1993).
- [7] K. Nagarajan, P.K. Talwalker, A. Nagana Goud, R.K. Shah, S.J. Shenoy and N.D. Desai, Ind. J. Chem., 27B, 1113(1988).
- [8] K. Nagarajan, P.K. Talwalker, A. Nagana Goud, R.K. Shah and S.J. Shenoy, Arzneimittel Forschung, 39, 548(1989).
- [9] S. Deepthi, K. Nagarajan and Vasantha Pattabhi, Acta Cryst., C55, 100(1999).
- [10] Enraf-Nonius CAD-4 software. Version 5.0. Enraf-Nonius, Delft, The Netherlands, 1989.
- [11] G.M. Sheldrick, SHELXS-97. Program for Crystal Structure Determination. University of Gottingen, Germany, (1997).
- [12] G.M. Sheldrick, SHELXL97. Program for Crystal Structure Refinement. University of Gottingen, Germany(1997).
- [13] B.A. Frenz, The Enraf-Nonius CAD-4 SDP- A Real-Time System for concurrent X-ray data collection and crystal structure solution. Computing in Crystallography, edited by H. Schenk, R. Olthof-Hazekamp, H. van Koningsveld & G.C. Bassi, Delft University Press. pp. 64 (1978).
- [14] Biosym Inc. InsightII. Biosym Inc., San Diego CA, USA. (1993).
- [15] K.A. Nirmala and D.S. SakeGowda, Acta Cryst. B37,1597(1981).
- [16] L. ZSOLNAI, ZORTEP. Molecular Graphics Program, University of Heidelberg, Germany (1997).